Key facts
- It has raised $3.0M; the latest was Later Stage VC in May 2025.
- Notable investors include BioVaria, Bioinvestimed, Dendis Capital, Garage Angels, Holecek Family Foundation — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for CasInvent
- ·The full record, as it builds
Funding rounds
No funding rounds for CasInvent are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CasInvent
Developer of therapeutic compounds designed for the treatment of selected malignancies. The company uses selective inhibitors of enzymes belonging to the Casein Kinase 1 (CK1) family that are responsible for the migration of leukemia cells into lymphoid organs, enabling doctors to help in the treatment of leukemias, lymphomas, and solid tumors.
- Sector
- Healthcare
- HQ
- Brno, Czech Republic
- Founded
- 2020
- Employees
- 9
- Website
- casinvent.com/
- Ownership
- Privately Held (backing)
CasInvent doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CasInvent shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CasInvent in its N-PORT filings yet. We sweep new filings monthly.